Join Prof. Jordi Monés, MD, PhD, on Friday, Sept. 5 at 13:48 local time for his talk "Phase 2a SIGLEC Study: Changes in Hyper-autofluorescence Area and RPE/Outer Retinal Layer Thickness Following a Single Injection of AVD-104 for the Treatment of Geographic Atrophy.” You can find him in Speakers’ Corner 1. #ophthalmology #retina #Euretina #geographicatrophy
Aviceda Therapeutics
Biotechnology Research
Cambridge, Massachusetts 6,141 followers
Aviceda is an innovative clinical-stage biotech company focused on the next generation of glyco-immune therapeutics.
About us
The Future of Glyco-therapeutics Aviceda Therapeutics is a disruptive clinical-stage biotech company focused on the next generation of immuno-modulators by harnessing the power of glycobiology to address the innate immune system and chronic non-resolving inflammation specifically and profoundly using a propriety HALOS platform Technology. Aviceda is developing glyco-immuno therapeutics targeting devastating ocular and systemic degenerative, fibrotic, and immuno-inflammatory diseases. A combination of cutting-edge technologies and deep biological insights form Aviceda’s engine of transformative product creation. Aviceda has combined the power of our glycobiology and glycochemistry platform with our proprietary nanoparticle technology (HALOS) to engineer transformative disease modifying medicines. Using our cell-based high-throughput screening (HTS) platform, we can rapidly screen, select, and optimize ligands based on maximum affinity and specificity for each different type of innate immune cell. Optimized ligands are tethered to our modular biodegradable nanoparticles using high precision conjugation chemistry to form biologically stable linkages. Our GCT nanoparticles are designed for optimal therapeutic durability and maximum therapeutic efficacy while utilizing the most effective route of administration. Aviceda’s platform is highly adaptable, enabling the development of a broad spectrum of therapeutics for immuno-inflammatory indications with large unmet medical needs.
- Website
-
https://www.avicedarx.com
External link for Aviceda Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Privately Held
- Founded
- 2018
Locations
-
Primary
Get directions
One Broadway
14th Floor
Cambridge, Massachusetts 02142, US
-
Get directions
700 Main Street
Cambridge, Massachusetts 02139, US
Employees at Aviceda Therapeutics
Updates
-
At the ASRS annual meeting at the Long Beach Convention Center on August 2, 2025, at 11:19 a.m., Eleanora Lad, MD, PhD, will present research on how targeting CD163+ retinal macrophages with AVD-104 may help restore photoreceptor function and improve vision in patients with geographic atrophy. #glycoimmunology #biotech #innovation #ophthalmology #retina #GA #AMD #macula
-
-
At the ASRS annual meeting at the Long Beach Convention Center on August 2, 2025, at 11:13 a.m., Carl Regillo, MD, will present findings from the Phase 2a SIGLEC study on AVD-104, highlighting changes in hyper-autofluorescence and RPE thickness from baseline to Month 3 in patients with geographic atrophy. #glycoimmunology #biotech #innovation #ophthalmology #retina #GA #AMD #macula
-
-
At the ARVO meeting in Salt Lake City, Utah, on May 7, 2025 at 2:30pm, Dr. Baruch D. Kuppermann will present findings on autofluorescence changes in GA patients after a single dose of AVD-104 in the SIGLEC Phase 2a study. #glycoimmunology #biotech #innovation #ophthalmology #retina #GA #AMD #macula
-
-
At the ARVO meeting in Salt Lake City, Utah, on May 7, 2025, from 10:15am- 12:45 pm, Diyan Patel, MS will present a poster on the use of polysialic acid nanoparticles to modulate macrophage-driven inflammation in age-related macular degeneration (AMD). #glycoimmunology #biotech #innovation #ophthalmology #retina #GA #AMD #macula
-
-
At the ARVO meeting in Salt Lake City, Utah, on May 4, 2025, from 1:00-2:45 pm, Victor German Sendra, PhD, will present a poster on the use of polysialic acid nanoparticles to modulate T cell-mediated immune responses as a potential mechanism of action for uveitis treatment. #glycoimmunology #biotech #innovation #ophthalmology #retina #GA #AMD #macula
-
-
At the Retina World Congress in Fort Lauderdale, Florida, on May 5, 2025, at 5:32 PM, Dr. Rishi P. Singh will share findings from the Phase 2a SIGLEC study, which assessed the safety and efficacy of a single dose of AVD-104 for the treatment of geographic atrophy. #glycoimmunology #biotech #innovation #ophthalmology #retina #GA #AMD #macula
-
-
Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors https://lnkd.in/e4Gdyb3y #glycoimmunology #biotech #innovation #ophthalmology #retina #GA #AMD #maculardegeneration
-
-
Aviceda Therapeutics Appoints Industry Veteran Dr. Jeffrey Nau Chief Executive Officer to Lead Next Phase of Growth and Innovation https://lnkd.in/e4uq-25b #glycoimmunology #biotech #innovation #ophthalmology #retina #GA #AMD #maculardegeneration
-
-
🎉 Exciting news! We're thrilled to announce two well-deserved promotions within our team! 👏 Amitkumar Lad, PhD has been promoted from Director, Chemistry, Manufacturing & Controls to Senior Director, Technical Development. With his exceptional leadership and expertise, Amit has consistently delivered outstanding results, and we're excited to see him excel in his new role. 👏 Dawn McNeal has been promoted from Clinical Trial Manager to Senior Clinical Program Manager. Dawn's dedication and meticulous approach to clinical trials have been invaluable to our success, and we're confident she'll continue to shine in her expanded responsibilities. Join us in congratulating Amit and Dawn on their achievements! #Promotions #CareerGrowth #Teamwork #Leadership #Opthalmology
-